Goldman Sachs Group Inc Harpoon Therapeutics, Inc. Transaction History

Goldman Sachs Group Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 May 14, 2024	SELL	$0.6 - $1.41 $8,981 - $21,106	-14,969 Reduced 11.83%	111,601 $81,000
Q4 2022 Feb 13, 2023	SELL	$0.6 - $1.41 $8,981 - $21,106	-14,969 Reduced 11.83%	111,601 $81,000
Q3 2022 May 14, 2024	SELL	$0.94 - $2.56 $77,409 - $210,816	-82,350 Reduced 39.42%	126,570 $123,000
Q3 2022 Nov 10, 2022	SELL	$0.94 - $2.56 $77,409 - $210,816	-82,350 Reduced 39.42%	126,570 $0
Q2 2022 May 14, 2024	BUY	$1.78 - $5.02 $371,877 - $1.05 Million	208,920 New	208,920 $399,000
Q2 2022 Aug 15, 2022	BUY	$1.78 - $5.02 $84,288 - $237,712	47,353 Added 29.31%	208,920 $399,000
Q1 2022 May 16, 2022	BUY	$3.54 - $8.08 $175,113 - $399,693	49,467 Added 44.13%	161,567 $803,000
Q4 2021 Feb 14, 2022	BUY	$5.69 - $7.83 $140,554 - $193,416	24,702 Added 28.26%	112,100 $847,000
Q3 2021 Nov 10, 2021	BUY	$7.88 - $14.0 $688,696 - $1.22 Million	87,398 New	87,398 $690,000

353K

Ticker HARP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 33,106,800
Description
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candi...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.